Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).
Our CompaniesNewsroomInsights

About PPF Group

About UsPeople and statutory bodiesFinancial results & statementsReports and documents

Social responsibility

Social responsibilitySustainability
For MediaContactsCareers
cs

News to Email

Get the latest press releases, interviews, podcasts, and insights. 

Subscribe To News

Follow us

For Media

  • Press Releases
  • Interviews and Podcasts
  • Subscribe To News
  • Downloads
  • Contacts

MAY BE OF INTEREST

  • Our Companies
  • Newsroom
  • Insights

Contacts

  • PPF Group Companies
  • Terms of use
  • Data protection
  • Sitemap
  • Cookies policy

2026 © PPF Group

Most often you are looking for

Annual ReportsInsightsVisions and StrategiesPress Releases

  • Insights

  • Biotech Market / Business Intelligence

Sotio Biotech

19/8/2025

March 2025 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions

by Jakub Jarolím, Business Intelligence Department

Share on social networks

Share on social networks

Print

Copy link

Market

Slow IPO season may be coming to an end, as four biotechs completed IPO of $100+ million

A slow season for biotech IPOs may be coming to an end. In September, four biopharmas have completed NASDAQ listings in which each raised more than $100 million, including Bicara with $315 million IPO. Most recently, Upstream Bio filed for IPO seeking to raise $100 million.

News detail

Antibody-Drug Conjugates

Elevation Oncology is axing development of its Claudin 18.2 ADC EO-3021 in Phase 1

Investigational Rina-S continues to show encouraging antitumor activity in ovarian cancer

News detail

Interleukin-15 and Interleukin-2

Mural Oncology to discontinue its Phase 3 trial of nemvaleukin plus pembrolizumab

Mural Oncology announced that the ARTISTRY-7 Phase 3 trial of nemvaleukin alfa in combination with pembrolizumab vs investigator’s choice chemotherapy in patients with platinum-resistant ovarian cancer (PROC) will not continue to final analysis and the company will cease development of nemvaleukin for PROC.

News detail

Cell Therapies

AZ to acquire EsoBiotec with CAR-T targeting BCMA in Phase 1 for up to $1 billion

The FDA has approved the IND application of CTD402 for the treatment of pediatric and adult patients with relapsed/refractory T-ALL/LBL, allowing for the start of a single-arm, open-label phase 1b/2 trial. The study will utilize a dose-finding design and aims to optimize dosing of CTD402 and accelerate clinical development. CTD402 is a universal CAR T-cell therapy that works by targeting CD7 that comes from healthy donors.

News detail

Other Innovative Treatment Areas

ITM presented positive topline Phase 3 data with 177Lu-edotreotide

ITM presented positive topline data from its Phase 3 COMPETE trial in patients with Grade 1 or Grade 2 somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

News detail

DISCLAIMER / SOTIO

Legal Notice

News detail